Achieving cost-neutrality with long-acting reversible contraceptive methods

Contraception

Volumn 91, Issue 1, 2015, Pages 49-56

  Trussell, James ^a   Hassan, Fareen ^b   Lowin, Julia ^b   Law, Amy ^c   Filonenko, Anna ^d  

^a PRINCETON UNIVERSITY   (United States)

^b IQVIA   (United States)

^c Bayer HealthCare Pharmaceuticals Inc   (United States)

^d BAYER PHARMA AG   (Germany)

Author keywords

Cost savings; Cost study; LARC; SARC; Unintended pregnancy

Indexed keywords

INJECTABLE CONTRACEPTIVE AGENT; LEVONORGESTREL; CONTRACEPTIVE AGENT; DELAYED RELEASE FORMULATION;

ADULT; ARTICLE; CONTRACEPTION; CONTRACEPTIVE PATCH; COPPER INTRAUTERINE DEVICE; COST CONTROL; FEMALE; FEMALE CONDOM; HEALTH CARE COST; HUMAN; LEVONORGESTREL RELEASING INTRAUTERINE SYSTEM; ORAL CONTRACEPTIVE USE; UNITED STATES; UNPLANNED PREGNANCY; ADMINISTRATION AND DOSAGE; ADVERSE EFFECTS; COHORT ANALYSIS; COMPARATIVE STUDY; COST; DELAYED RELEASE FORMULATION; DRUG COST; ECONOMIC MODEL; ECONOMICS; FEMALE CONTRACEPTIVE DEVICE; PREGNANCY; TIME FACTOR; TRANSDERMAL PATCH; YOUNG ADULT;

ADULT; COHORT STUDIES; CONTRACEPTION; CONTRACEPTIVE AGENTS, FEMALE; CONTRACEPTIVE DEVICES, FEMALE; COST SAVINGS; COSTS AND COST ANALYSIS; DELAYED-ACTION PREPARATIONS; DRUG COSTS; FEMALE; HEALTH CARE COSTS; HUMANS; MODELS, ECONOMIC; PREGNANCY; PREGNANCY, UNPLANNED; TIME FACTORS; TRANSDERMAL PATCH; UNITED STATES; YOUNG ADULT;

EID: 84920525116     PISSN: 00107824     EISSN: 18790518     Source Type: Journal    
DOI: 10.1016/j.contraception.2014.08.011     Document Type: Article

References (21)

1. Trussell J, Henry N, Hassan F, Prezioso A, Law A, Filonenko A. Burden of unintended pregnancy in the United States: potential savings with increased use of long-acting reversible contraception. Contraception 2012;87(2):154-61.
2. Sonfield A, Gold RB. Public funding for family planning, sterilization and abortion services, FY 1980-2010. New York: Guttmacher Institute; 2012 [Available from:http://www.guttmacher.org/pubs/ Public-Funding-FP-2010.pdf].
3. Monea E, Thomas A. Unintended pregnancy and taxpayer spending. Perspect Sex Reprod Health 2011;43(2):88-93.
4. Finer LB, Darroch JE, Frost JJ. US agencies providing publicly funded contraceptive services in 1999. Perspect Sex Reprod Health 2002;34(1):15-24.
5. Moreau C, Cleland K, Trussell J. Contraceptive discontinuation attributed to method dissatisfaction in the United States. Contraception 2007;76(4):267-72.
6. Trussell J. Contraceptive failure in the United States. Contraception 2011;83:397-404.
7. Jones J, Mosher W, Daniels K. Current contraceptive use in the United States, 2006 -2010, and changes in patterns of use since 1995. National health statistics reports; no 60. Hyattsville, MD: National Center for Health Statistics; 2012.
8. Mavranezouli I. The cost-effectiveness of long-acting reversible contraceptive methods in the UK: analysis based on a decision-analytic model developed for a National Institute for Health and Clinical Excellence (NICE) clinical practice guideline. Hum Reprod 2008;23 (6):1338-45.
9. Trussell J, Hassan F, Henry N, Pocoski J, Law A, Filonenko A. Cost-effectiveness analysis of levonorgestrel-releasing intrauterine system (LNG-IUS) 13.5 mg in contraception. Contraception 2014;89(5):451-9.
10. Trussell J. The cost of unintended pregnancy in the United States. Contraception 2007;75:168-70.
11. Mosher WD, Jones J, Abma JC. Intended and unintended births in the United States: 1982-2010. National health statistics reports, no. 55. Hyattsville, MD: National Center for Health Statistics; 2012.
12. Vaughan B, Trussell J, Kost K, Singh S, Jones R. Discontinuation and resumption of contraceptive use: results from the 2002 National Survey of Family Growth. Contraception 2008;78(4):271-83.
13. Wolters Kluwer Health. Medi-Span master drug database. Available from: http://www.medi-span.com/drug-pricing-analysis-pricerx.aspx 2012.
14. Centers for Medicare & Medicaid Services. Medicare physician fee schedule, CPT code book and Medicare outpatient prospective payment system. Available from https://www.cms.gov/home/medicare.asp 2012.
15. HCUPnet. Healthcare cost and utilization project. Rockville, MD: Agency for Healthcare Research and Quality; 2012 [Available from: http://hcupnet.ahrq.gov].
16. Medicare Payment Advisory Commission. Report to the Congress: Medicare payment policy - section 2b physician services. Available from http://www.medpac.gov/chapters/Mar07-Ch02b.pdf 2007.
17. Chiou CF, Trussell J, Reyes E, Knight K, Wallace J, Udani J, et al. Economic analysis of contraceptives for women. Contraception 2003;68:3-0.
18. Peipert JF, Zhao Q, Allsworth JE, Petrosky E, Madden T, Eisenberg D, et al. Continuation and satisfaction of reversible contraception. Obstet Gynecol 2011;117(5):1105-13.
19. Ventura SJ, Curtin SC, Abma JC, Henshaw SK. Estimated pregnancy rates and rates of pregnancy outcomes for the United States, 1990-2008. National vital statistics reports; vol 60 no 7. Hyattsville, MD: National Center for Health Statistics; 2012.
20. Hoover KW, Tao G, Kent CK. Trends in the diagnosis and treatment of ectopic pregnancy in the United States. Obstet Gynecol 2010;115(3):495-502.
21. Finer LB, Henshaw SK. Disparities in rates of unintended pregnancy in the United States, 1994 and 2001. Perspect Sex Reprod Health 2006;38(2):90-6.